With only a few studies identifying potential biomarkers for response to BRAF-targeted therapy [4,5,6], we set out to determine whether aneuploidy within the collected melanoma tumor tissue might predict the success of BRAF-targeted treatment or immunotherapy and overall disease response. This evidence concerns the gene BRAF and neoplasm.